What Is HCG?

Published September 2026 · Patriot Labs Research Team · ~13 min read

A pregnancy hormone, borrowed by the laboratory

Most of the compounds in this catalogue are small synthetic chains a few residues long, assembled on a machine. HCG is the exception in almost every respect. It is a natural hormone, produced by the placenta rather than a peptide synthesizer; it is large, on the order of a small protein; and it is decorated so heavily with sugar that carbohydrate makes up nearly a third of its weight. Its biological day job is to sustain early pregnancy — the developing placenta releases it to keep the ovary’s corpus luteum alive and producing progesterone during the weeks before the placenta can take over that role itself. It is, in the plainest terms, the hormone a pregnancy test looks for.

So why does a hormone with that résumé sit in a research-peptide catalogue at all? The answer is the receptor. HCG binds the same receptor as luteinizing hormone (LH), the pituitary gonadotropin that sits at the bottom of the hypothalamic–pituitary–gonadal (HPG) axis, and it activates that receptor at least as strongly as LH does. Because HCG has historically been abundant, easy to obtain, and far longer-lasting than LH, endocrinologists adopted it decades ago as a convenient, durable surrogate for LH in experiments — a way to switch on the LH receptor in a cell or an animal model and watch what happens. That is the thread that runs through the whole story: HCG is studied less as a molecule in its own right than as a standard, well-behaved tool for probing gonadotropin signaling. To place it in the wider family the catalogue carries, the site’s overview of what peptides are is the natural starting point, and its guide to the HPG-axis peptides sets HCG beside the upstream signals it is most often studied alongside.

Two subunits: one shared, one unique

HCG belongs to the glycoprotein hormone family, a small club of four hormones — HCG, LH, follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH) — that all share the same basic architecture. Each is a heterodimer: two different protein chains, an alpha subunit and a beta subunit, held together not by a covalent bond but by the way they fold around each other. Neither chain does anything useful alone; the hormone only works as the assembled pair.¹

The clever part of the family’s design is that the alpha subunit is identical across all four hormones. It is a 92-amino-acid chain, the product of a single gene, and the same alpha appears in HCG, LH, FSH, and TSH without alteration. What distinguishes one hormone from another is entirely the beta subunit. HCG’s beta subunit is 145 amino acids long and is the piece that gives the hormone its identity — its specific shape, its receptor preference, and the epitopes that immunoassays recognize. In other words, HCG is “the shared alpha plus the HCG-specific beta,” and that modular logic is worth holding onto, because it explains both why HCG resembles its relatives and why it is still distinct.

The resemblance it matters most to is LH. The beta subunits of HCG and LH are strikingly similar — they share roughly 85 percent identity across their first 114 residues — which is the structural reason the two hormones recognize the same receptor and produce broadly the same signal.¹ Where HCG’s beta chain departs from LH’s is at the very end: HCG-beta carries an extra stretch of about two dozen residues at its carboxy terminus, the carboxy-terminal peptide (CTP), that LH-beta simply does not have. That short tail turns out to be one of the most consequential features of the whole molecule, and it is the subject of the next section.

The sugar coat and the long tail

If the two-subunit fold is HCG’s skeleton, the carbohydrate is its overcoat. HCG is heavily glycosylated — roughly 30 percent of the finished molecule’s mass is sugar rather than protein — and the total molecular weight lands around 36 to 37 kilodaltons, most sources citing a figure near 36.7 kDa for the intact dimer.¹ The sugars hang off the protein at eight sites in total. The alpha subunit carries two N-linked glycans (sugars attached to asparagine residues); the beta subunit carries two more N-linked glycans plus four O-linked glycans (attached to serine residues), and those four O-linked chains sit on the carboxy-terminal peptide.

That concentration of O-linked, heavily sialylated sugar on the CTP is not decorative. Sialic acid — the negatively charged sugar that caps many of these chains — slows the rate at which the liver clears a glycoprotein from circulation. The more sialic acid a molecule carries, the longer it lingers. HCG carries a great deal of it, and the result is a hormone with a remarkably long half-life: where LH is cleared in a matter of tens of minutes to a few hours, HCG’s terminal half-life is measured on the order of a day, commonly cited in the range of 24 to 36 hours. Same receptor, very different duration of action — and the difference is written almost entirely in the glycosylation of that extra tail.

Researchers established the point elegantly by borrowing the tail. In a now-classic 1992 experiment, investigators fused HCG’s carboxy-terminal peptide onto the beta subunit of FSH and produced a long-acting FSH analogue — the design principle that later became the recombinant fertility drug corifollitropin alfa.² The lesson generalizes well beyond HCG: the CTP is a portable half-life-extension module, and its story is a clean illustration of how a small structural feature translates into a large pharmacokinetic difference. For readers coming from the small-peptide side of the catalogue, this is also a useful contrast — the reasons a glycoprotein like HCG persists in circulation are entirely different from the reasons a short synthetic chain is stabilized, a theme the guide on how peptides degrade takes up from the peptide direction.

HCG, beta-hCG, and the glycoform family

Search for this molecule and the terminology multiplies quickly, so it helps to sort the labels. HCG or intact hCG refers to the complete, assembled heterodimer — the biologically active hormone. Beta-hCG (or free beta subunit) refers to the HCG-specific chain on its own; it is what many diagnostic tests are built to detect, because its uniqueness makes it a clean fingerprint for the hormone. There is also a beta-core fragment, a clipped-down piece of the beta subunit that appears as a breakdown product. These are not interchangeable names for one thing; they are genuinely different molecular species, and confusing them is a common source of error when reading an assay result or a certificate.

Beyond those, HCG exists in more than one glycoform — versions of the same protein backbone carrying different sugar patterns. The most-discussed variant is hyperglycosylated HCG (hCG-H), a form with larger, more complex carbohydrate structures that has been studied in the context of early trophoblast invasion and some tumor biology. The existence of these variants is one of the things that makes HCG harder to pin down analytically than a small peptide: “HCG” is really a population of closely related molecules rather than one exact structure, and any credible characterization has to be clear about which species it is measuring. The site’s guide to reading a certificate of analysis makes the general version of this point repeatedly — the name on the label is a claim, and the analytics are what confirm which molecule is actually present.

From a 1927 mouse assay to recombinant cells

HCG has one of the oldest and best-documented origin stories in endocrinology. In 1927–1928, the Berlin gynaecologist Selmar Aschheim and the endocrinologist Bernhard Zondek demonstrated that the urine of pregnant women contained a substance capable of stimulating the ovaries of immature female mice.³ Injecting that urine into young mice produced characteristic ovarian changes; the reaction became known as the Aschheim–Zondek (A–Z) test, and it was the first reliable pregnancy test in history as well as the first practical demonstration of what we now call HCG. For decades “the pregnancy hormone” and HCG were effectively synonymous, and the hormone’s early availability in pregnancy urine made it one of the most accessible gonadotropins to study.

That accessibility shaped how the material was produced for most of the twentieth century. Because pregnancy urine is a rich source, HCG was manufactured by extraction and purification from the pooled urine of pregnant women — the origin of the long-standing urinary preparations. Its subunit structure was worked out in the 1970s, when the alpha/beta architecture of the glycoprotein hormone family was established and the shared-alpha logic became clear. The modern chapter arrived around 2000 with recombinant HCG: choriogonadotropin alfa, produced in cultured Chinese hamster ovary (CHO) cells rather than harvested from urine, offered a defined, reproducible alternative to the extracted material.⁴ The arc from a 1927 mouse bioassay to a recombinant glycoprotein made in a bioreactor is a compact history of twentieth-century endocrinology in a single molecule — and it is a very different manufacturing arc from the one described in the site’s account of how peptides are made, because a glycoprotein cannot be built by solid-phase synthesis at all; it has to be expressed by living cells that can attach the sugars.

The pathways the studies point to

HCG’s activity all runs through one receptor: the luteinizing hormone / choriogonadotropin receptor (LHCGR), a G-protein-coupled receptor of the same broad rhodopsin-like class as many hormone and neurotransmitter receptors. LHCGR sits on the gonadal cells that make steroid hormones — the Leydig cells of the testis and the theca, granulosa, and luteal cells of the ovary. When HCG binds, the receptor’s principal move is to couple to the Gs protein and switch on adenylyl cyclase, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). That cascade turns up the cell’s steroidogenic machinery — the transport of cholesterol into mitochondria and the chain of enzymes that convert it toward steroid hormones — which is why, in laboratory models, LHCGR activation by HCG is studied as a driver of gonadal steroidogenesis. The receptor can also engage other routes, including the Gq / phospholipase-C arm that mobilizes calcium and the beta-arrestin / ERK pathway associated with longer-term cellular responses.

The genuinely interesting wrinkle, and a lively area of recent research, is that HCG and LH are not simply interchangeable at their shared receptor. Work published in Scientific Reports in 2017 characterized the two as “biased agonists” — molecules that bind the same receptor but push its downstream pathways in different proportions.⁵ In that study, recombinant HCG was substantially more potent than recombinant LH at the cAMP arm, with an EC₅₀ roughly sixteen times lower in one cell system, and about fifteen times more potent at driving progesterone output; LH, by contrast, reached only about half of HCG’s maximal progesterone response, behaving as a partial agonist on that particular readout. The practical upshot for a research audience is that HCG is not just “LH that lasts longer.” It is a distinct ligand with its own signaling signature, which is exactly what makes the pair so useful as tools for dissecting how a single receptor can route different inputs into different cellular outputs. It is a very different kind of mechanism story from the upstream one told by Kisspeptin-10, which acts high in the HPG axis to trigger GnRH release; HCG acts at the bottom of the same axis, standing in for the LH signal that the pituitary would normally send.

The research record

By the standards of this catalogue, HCG is almost unique in how thoroughly it has been studied. It is one of the most extensively characterized hormones in all of endocrinology, with a century of literature spanning its biochemistry, its subunit structure, its receptor pharmacology, its glycobiology, and its role in reproductive physiology. Its receptor mechanism is well defined, its structure is solved, and it has served as a reference gonadotropin in countless laboratory studies. That depth is the opposite of the situation for many novel research peptides, where the literature is thin and preliminary.

The important caveat is about what that literature is about. The overwhelming majority of the human clinical record on HCG concerns its endogenous role in pregnancy and its use as an approved medicine within reproductive medicine — contexts that are studied in patients, under medical supervision, and that say nothing about what a research-grade preparation does for any individual outside that setting. A deep evidence base for a hormone’s biology is not the same thing as evidence for a research chemical’s use, and the two should never be conflated. The table below summarizes what the record establishes and where its edges are.

An approved biologic, not a research peptide

Here is where HCG’s story diverges most sharply from the rest of the catalogue, and the distinction is worth stating precisely because it is easy to blur. Peptides sold and studied outside the approved-drug system have drawn growing FDA attention, and on July 23–24, 2026 the agency’s Pharmacy Compounding Advisory Committee met to review a slate of seven peptides as candidates for the 503A bulk drug substances list that governs what licensed pharmacies may compound. Those seven were BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax.⁶ HCG was not on that list — and the reason it was not is instructive.

Each of those seven is a novel peptide without a long-standing US approved-drug pathway; that is precisely why a compounding committee was weighing whether pharmacies could prepare them at all. HCG is the opposite case. It is a long-approved biologic drug substance, the active ingredient in prescription medicines that have been on the market for decades — the urinary preparations historically sold as Pregnyl and Novarel, and the recombinant version, choriogonadotropin alfa, sold as Ovidrel — with recognized pharmacopeial standards and an International Standard behind its potency.⁷ A hormone with that pedigree simply was not the kind of substance the July 2026 review was convened to examine. That fact does two things at once: it explains why HCG sits in a different regulatory bucket from the research peptides beside it, and it makes the research-use framing more important rather than less.

Because none of that approved-drug history describes the footing on which a research supplier operates. The existence of FDA-approved medicines containing HCG is a fact about those specific, regulated products, prescribed and dispensed through the healthcare system. Research-grade HCG is a separate thing: laboratory material, characterized for identity and purity, and sold for in-vitro research use only. The site’s guide to how peptides differ from drugs and biologics covers exactly why an approved biologic, a compounded preparation, and a research chemical are three different categories even when the underlying molecule is the same — a distinction that HCG, as an approved biologic offered here strictly as research material, illustrates about as clearly as any molecule can.

Bench practice: characterizing a glycoprotein

Characterizing HCG is a genuinely different exercise from characterizing a short synthetic peptide, and the difference comes straight from the chemistry above. A small peptide has one exact mass and a sequence that can be confirmed with a single mass-spectrometry reading and a purity number from reversed-phase HPLC. HCG has neither luxury: it is a two-chain glycoprotein whose sugars vary from molecule to molecule, so it does not present as one sharp mass, and its “identity” is a matter of the correct assembled dimer bearing the right kind of glycosylation rather than a single tidy formula.

The tools reflect that. Identity and quantity for HCG lean heavily on immunoassays built around antibodies that recognize defined epitopes — distinguishing intact dimer from free beta subunit from the beta-core fragment — supplemented by mass spectrometry and dedicated glycan analysis to describe the carbohydrate. Potency is where HCG’s pharmacopeial pedigree shows: rather than a simple percentage, HCG activity is expressed in International Units (IU), defined against a WHO International Standard. The current line of standards runs from the 5th International Standard (code 07/364, established 2009) to the 6th (18/244), each a batch of highly purified intact urinary HCG whose potency is assigned by both in-vivo bioassay — historically the rat seminal-vesicle-weight and mouse uterine-weight methods — and by large panels of immunoassays, so that a unit measured in one laboratory means the same thing in another.⁸ That an IU is even necessary tells the whole story: a mass measurement alone cannot fully capture a heterogeneous glycoprotein’s activity.

Storage follows the general rules for the class, with the usual glycoprotein caveats. HCG is supplied as a lyophilised (freeze-dried) solid, and as a dry powder kept cold, sealed, and protected from moisture it is comparatively stable; once reconstituted it is far more vulnerable, and protection from repeated freeze–thaw cycling and from microbial contamination becomes the practical concern, since a large folded protein is more easily damaged by rough handling than a short peptide is. The site’s storage guide covers the practical handling, and its COA explainer covers what a credible certificate should show; none of that is a use instruction, only the analytical hygiene that lets a laboratory trust that what is in the vial matches the label.

What the evidence does not establish

HCG attracts more everyday associations than almost any hormone on this list, and the honest move is to draw the boundary plainly. The molecule’s biology is real and deeply documented, and its role in pregnancy and in approved reproductive medicines is a matter of settled science. But that record describes an endogenous hormone and a set of regulated medical products; it does not describe, and should not be read as describing, what a research-grade preparation does for any person. Nothing in the structural, mechanistic, or historical account above is a claim about outcomes, and none of it is a use instruction.

The popular framings that cling to the letters “HCG” — in particular the various consumer and athletic protocols that have attached themselves to the hormone over the years — sit entirely outside what this guide addresses and, in several well-known cases, outside what the science supports at all. A research audience is best served by ignoring that layer completely and treating HCG for what it is on the bench: a well-characterized glycoprotein hormone and a durable LH-receptor agonist, useful precisely because its structure and signaling are so thoroughly mapped. For placing it against the compounds it shares an axis with, the guide to HPG-axis peptides and the explainer on Kisspeptin-10 are the honest reference points.

The honest summary is that HCG is a large, sugar-coated glycoprotein hormone with a century of biology behind it, a clearly defined receptor mechanism, and a genuinely unusual place in this catalogue as an approved biologic supplied strictly as research material — and that this combination is exactly what makes it a legitimate subject for laboratory investigation, and exactly why it belongs in a research setting and nowhere else.

Frequently asked questions

Is HCG actually a peptide?

Not in the sense that most of the catalogue is. HCG is a large glycoprotein hormone, not a small synthetic peptide. It is a two-subunit molecule of roughly 36 to 37 kilodaltons, almost a third of that mass carbohydrate rather than amino acids, and it is not built on a peptide synthesizer the way a chain such as BPC-157 is. It is grouped with the peptides because it belongs to the same broad world of signaling molecules and is studied with overlapping tools, but structurally it sits closer to a small protein. That distinction matters most when it comes to how the molecule is made and how it is characterized, both of which differ from the routine for a short synthetic peptide.

What is the difference between HCG and LH?

They are close relatives that act at the same receptor but are not identical. Luteinizing hormone (LH) and HCG both bind the LH/choriogonadotropin receptor (LHCGR), and their beta subunits share roughly 85 percent identity across their first 114 residues, which is why HCG behaves as an LH mimetic and is used as an LH surrogate in research. The two main differences are the tail and the timing. HCG’s beta subunit carries an extra carboxy-terminal peptide that LH lacks, and the heavy sialylated glycosylation on that tail gives HCG a far longer circulating half-life. Laboratory work has also shown the two are biased agonists at the shared receptor: HCG is markedly more potent at driving the cAMP and steroidogenic arm, while LH engages other pathways relatively more.

Is HCG approved by the FDA?

The molecule has a long approved-drug history, which is exactly what sets it apart from most research peptides. HCG is the active substance in long-established prescription medicines, both the urinary preparations historically marketed as Pregnyl and Novarel and the recombinant version, choriogonadotropin alfa, marketed as Ovidrel. Those are FDA-approved products in their own separate, tightly regulated world. Research-grade HCG supplied by Patriot Labs is a different thing entirely: laboratory material characterized for identity and purity and sold for in-vitro research use only. The existence of approved medicines that contain HCG is a regulatory fact about those products, not a statement about the research material.

Was HCG part of the July 2026 FDA peptide compounding review?

No. On July 23 and 24, 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides as candidates for the 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax. HCG was not among them, and it sits in a different regulatory category from those substances. Where each of those seven is a novel peptide without a US approved-drug pathway, HCG is a long-approved biologic drug substance with recognized pharmacopeial standards behind it. The compounding review concerned whether licensed pharmacies could prepare those specific research-associated peptides for patients; it did not touch HCG, whose status as an approved substance was never the question.

Is HCG intended for human use?

No. HCG supplied by Patriot Labs is sold strictly for in-vitro research and laboratory use only. It is not for human or veterinary consumption, and nothing in this guide describes how to administer it. Approved medicines that contain HCG are separate, nationally regulated products prescribed and dispensed through the healthcare system; research-grade HCG is a laboratory material characterized for identity and purity, and that is the only footing on which it is offered here. For the practical side of sourcing verified material, see the guide on storing research peptides and the COA explainer.

References

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes glycoprotein-hormone chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.